Best Fluid Therapy Podcasts (2026)

1
New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates 21:18

Play Pause

20d ago21:18

21:18

How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new survey study comparing perspectives from fellowship program directors and recent graduates on surgical volumes, teaching tools, autonomy, and competency benchmarks. The…

1
Wet AMD and Next-Generation Therapies 17:51

28d ago17:51

17:51

How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching f…

1
DME, DR, and Next-Generation Therapies 17:19

28d ago17:19

17:19

How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dos…

1
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3) 28:51

1M ago28:51

28:51

Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes…

1
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3) 27:04

1M ago27:04

27:04

Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter …

1
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3) 29:02

1M ago29:02

29:02

In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses th…

1
Global Discussions in GA: Educating Patients and Encouraging Follow-Up 22:49

1M ago22:49

22:49

How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients a…

1
Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring 13:00

1M ago13:00

13:00

At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and…

1
Endophthalmitis Rates With and Without Antibiotic Prophylaxis 15:36

2M ago15:36

15:36

Does antibiotic prophylaxis prior to intravitreal injection affect the risk of endophthalmitis? Join New Retina Radio Journal Club with VBS moderator Alexis Warren, MD, as she and panelists Sruthi Arepalli, MD, and Jesse Sengillo, MD, sort out the details of a recent paper and discuss whether these findings alter clinical practice.…

1
The Nuts and Bolts of GA Therapy: Wrapping Up the Conversation 21:55

2M ago21:55

21:55

How do you decide when GA patients are ready for complement inhibition—and how do you keep them on therapy in the real world? In episode 3 of The Nuts and Bolts of GA Therapy, moderator Charles Wykoff, MD, PhD, speaks with Kenneth Fan, MD, MBA, and Sruthi Arepalli, MD, about early vs conservative initiation, nuanced counseling on expectations and s…

1
AAO '25: GLP-1s and AMD, and Parity in Retina Care 32:30

2M ago32:30

32:30

What do GLP-1 receptor agonists mean for the future of retinal disease? Aleksandra Rachitskaya, MD, joins us to review the ever-evolving data on the relationship between retinal disease and GLP-1 RA use. Could these drugs protect against the development of retinal disease? And Julia Haller, MD, explains her vision of what the future of retina looks…

1
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE 16:27

2M ago16:27

16:27

Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME. And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does ava…

1
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease 27:20

2M ago27:20

27:20

The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offered a survey of developmental projects in dry AMD. What should we look forward to? And Michel Michaelides, MD, shares details from the DRAGON study, which examined the safety and efficacy of tinlarebant (Belite …

1
The Nuts and Bolts of GA Therapy: The Discussions Continue 30:08

2M ago30:08

30:08

How do you create clear, durable treatment plans for real-world GA patients? In episode 2 of The Nuts and Bolts of GA Therapy, host Charles Wykoff, MD, PhD, joins Hasenin Al-khersan, MD, and Nakul Singh, MD, to dissect real-world cases and discuss choosing monthly or EOM week dosing regimens, engaging caregivers, and reconciling clinical trial data…

1
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR 25:54

2M ago25:54

25:54

Could optogenetics represent the innovative thinking needed to restore some function in retinitis pigmentosa (RP) patients? Allen Ho, MD, joins us to discuss the state of play in optogenetics, specifically regarding MCO-010 (Nanoscope Therapeutics). What have we seen in the several years since the first patients with RP were dosed with MCO-010 in t…

1
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care 19:50

3M ago19:50

19:50

How do costs and reimbursements shape practice patterns regarding panretinal photocoagulation (PRP)? Niki Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new time-driven activity-based costing study by Berkowitz et al. The panel explores how procedure time, margins, and CMS reimbursement affect the role…

1
The Nuts and Bolts of GA Therapy: The Opening Sessions 22:16

3M ago22:16

22:16

How do retina specialists first broach the topic of complement inhibition for GA therapy? In episode 1 of this miniseries, moderator Charles Wykoff, MD, PhD, speaks with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD, about timing treatment conversations, managing patients with one good and one bad eye, and addressing whether patients can main…

1
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision 15:37

3M ago15:37

15:37

How should retina specialists reframe their approach to GA therapy? In the final episode of this New Retina Radio miniseries, moderator John Kitchens, MD joins experts Margaret Chang, MD, MS; David Eichenbaum, MD; and Ferhina Ali, MD, MPH, to explore how to shift doctor mindsets from restoring vision to preserving it. The panel discusses challenges…

1
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation 15:57

3M ago15:57

15:57

Should GA therapy start monthly—or is less-than-monthly treatment enough? In episode 3 of this New Retina Radio miniseries, moderator John Kitchens, MD joins David Eichenbaum, MD; Margaret Chang, MD, MS; and Ferhina Ali, MD, MPH, to share best practices in real-world GA care. The panel debates dosing strategy in light of long-term data, compares sa…

1
Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations 18:31

3M ago18:31

18:31

How do you educate and empower patients to make informed decisions about geographic atrophy (GA) therapy? In episode 2 of this New Retina Radio miniseries, moderator John Kitchens, MD guides Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD, through practical strategies for patient education. The panel covers plain-language ana…

1
Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention 24:18

3M ago24:18

24:18

What does it mean to truly keep patients at the center of geographic atrophy (GA) therapy? In this first episode of a four-part New Retina Radio miniseries, moderator John Kitchens, MD, leads a discussion with experts Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD. The panel explores the social impact of GA and highlight the…

1
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab 17:31

3M ago17:31

17:31

What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentech/Roche) and are switched to high-dose aflibercept (Eylea HD, Regeneron)? Ben Young, MD, moderates a discussion with Pheobe Mellen, MD, and Jordan Deaner, MD, exploring real-world outcomes from a retrospective …

1
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR 33:52

4M ago33:52

33:52

What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observ…

1
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders 23:09

5M ago23:09

23:09

Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes afte…

1
New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy 16:48

5M ago16:48

16:48

What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to discuss a new retrospective cohort study by Rahimy et al. The panel explores how obstructive sleep apnea impacts the progression of diabetic retinopathy and …

1
The State of Geographic Atrophy Around the Globe: Part 1 of 2 12:14

6M ago12:14

12:14

The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina speci…

1
The State of Geographic Atrophy Around the Globe: Part 2 of 2 11:09

6M ago11:09

11:09

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed…

1
Diabetic Retinopathy Severity and Income Status 19:47

6M ago19:47

19:47

Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe Mellen, MD, and Jordan Deaner, MD, about a new retrospective cohort study from the Duke Eye Center than examines differences in DR severity at presentation between patients from the lowest- and hi…

1
GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates 7:58

6M ago7:58

7:58

How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.…

1
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy 11:19

6M ago11:19

11:19

What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.…

1
Evidencing paediatric key capabilities in the 2021 curriculum 17:51

6M ago17:51

17:51

Dr Mari Roberts, Dr Gethin Pugh and Dr Julia Parnell talk with Dr Laurence Hulatt, Paediatric Anaesthetic Consultant in Plymouth about the APAGBI-RCoA Guidance on How to evidence paediatric key capabilities in the 2021 curriculum. You can find the guidance here: https://www.apagbi.org.uk/education-and-training/educational-resources Mari is a Paedia…

1
Photobiomodulation for Age-related Macular Degeneration 18:57

7M ago18:57

18:57

What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study’s da…

1
Duke AVS Clips: PVR, DR, Imaging, and MTM 18:00

7M ago18:00

18:00

Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative vitreoretinopathy, Majda Hadziahmetovic, MD, shares new data on the effect of GLP-1 receptor agonists on diabetic retinopathy, Aleksandra V. Rachitskaya, MD, explains the value of multimodal Ima…

1
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI 12:25

7M ago12:25

12:25

Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal conditions that can manifest later in life, Jason Fan, MD, explains trends in anesthesia use for open-globe surgery, and Glenn J. Jaffe, MD, examines the role of AI in retina clinical trials.…

1
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs 16:31

7M ago16:31

16:31

During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her experiences delivering subretinal gene therapy, David Zacks, MD, PhD, explored important factors in retinal detachment repair, Xi Chen, MD, PhD, highlighted the various surgical approaches for young …

1
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data 24:25

7M ago24:25

24:25

Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which exam…

1
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline 22:47

8M ago22:47

22:47

Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-…

1
GLP-1s and Risk of Age-Related Ocular Disease 17:51

8M ago17:51

17:51

How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to examine a retrospective study published in Ophthalmology using TriNetX data to compare 5-year ocular outcomes across medication cohorts. Do these data suggest a prot…

1
Fellow Eye RRD Risk per IRIS Registry 16:42

8M ago16:42

16:42

Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repaired? What concomitant conditions do fellow eyes with RRD have? What risk factors exist for fellow eye RRD? And which procedures are used to repair fellow eye RRD? Moderator Barton Blackorby, MD, and panelists L…

1
Rates of Ocular AEs After Faricimab Injection 18:13

10M ago18:13

18:13

What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data s…

1
Treating Geographic Atrophy (GA) In Your Practice 19:18

10M ago19:18

19:18

Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.…

1
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy 22:07

10M ago22:07

22:07

Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.By Retina Today

1
Using OCT Angiography to Distinguish RVO and RAO 17:36

12M ago17:36

17:36

How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which …

1
OCT Angiography in a Real-world CSR Case 17:59

12M ago17:59

17:59

What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a g…

1
Switching from Aflibercept to Faricimab in Wet AMD Patients 22:00

1y ago22:00

22:00

Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use fi…

1
Regional anaesthesia for children - Part Three 24:32

1y ago24:32

24:32

Dr Rishi Diwan talks with Dr Laurence Hulatt, Paediatric Anaesthetic Consultant in Plymouth, about his favourite approach to block the brachial plexus in children. Dr Diwan is a Consultant Paediatric Anaesthetist and the Acute Pain Lead at Alder Hey Children's Hospital. He tells us about his favourite paediatric block, why he likes it, and shares s…

1
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment? 16:50

1y ago16:50

16:50

What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitami…

1
Regional anaesthesia for children - Part Two 25:17

1y ago25:17

25:17

Dr Steve Roberts and Dr Anisa Bhettay talk with Dr Laurence Hulatt, Paediatric Anaesthetic Consultant in Plymouth, about their favourite regional anaesthetic blocks in children. Dr Roberts is a Consultant Paediatric Anaesthetist at Alder Hey Children's Hospital - he talks about how he developed his paediatric regional anaesthesia skills and shares …

1
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's 31:38

1y ago31:38

31:38

How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database review of real-world patients with proliferative DR revealed how few patients are concordant with the strict dosing schedule of Protocol S, and shares which baseline factors were linked to lack …

1
Regional anaesthesia for children - Part One 26:09

1y ago26:09

26:09

Dr Annabel Pearson and Dr Catalina Stendall talk with Dr Laurence Hulatt, Paediatric Anaesthetic Consultant in Plymouth, about the development of the Paediatric Plan A blocks for regional anaesthesia in children. Dr Pearson is a Consultant Paediatric Anaesthetist in Bristol - she tells us about the inception of the Plan A paediatric blocks and tell…